The role of p53 gene in lung cancer with special emphasis on hereditary types by Rurańska, B. et al.
THE ROLE OF P53 GENE IN LUNG CANCER WITH SPECIAL EMPHASIS ON HEREDITARY
TYPES
B. Ruranska, M. Stawicka, D. Godlewski
Department of Cancer Prevention and Epidemiology at the Wielkopolska Oncological Center
Lung cancer is the most common type
of cancer affecting men and the fifth most
frequent female cancer. The survival rate
related to lung cancer is low, with the 5-year
survival amounting to 10-13% in highly
advanced countries. In Poland lung cancer
survival does not exceed 5%.
The major causes of lung cancer
incidence include tobacco smoking,
environmental factors and genetic
predisposition. The most frequent genetic
modifications observed in lung cancer cells are
mutations in the mye, ras and/or erb1 genes.
The p53 gene has been located on the
short arm of chromosome 17 and has been
found to consist of 11 exons with the first one
being non-coding. The analysis of its sequence
in different species resulted in identifying five
highly conservative regions, including exons 1,
4, 5, 7 and 8. The p53 has been classified as a
suppresser gene.
The p53 protein is a nuclear
phosphoprotein composed of 393 amino-acids.
This protein is active in the two most important
stages of the cellular cycle: during the transition
between phases G1 and S and between phases
G2 and M. The function of p53 can be described
as ensuring the integrity of the genome by
preventing replication of the damaged DNA and
cell division. When the repair process fails, p53
triggers the apoptosis of cells. In addition to the
regulatory function, p53 acts also as a
transcription agent.
Mutations in p53 are responsible for
60% of cases of human lung cancer. The
mutations are most often found in microcellular
lung cancer (70%) and are less frequent in the
cases of adenoid lung cancer (33%). The most
common mutations related to lung cancers
include: transversions of the G:C/AT type,
missense mutations, nonsense mutations and
deletions. These mutations occur in as many as
100 various locations but the most characteristic
ones for lung cancer are found in codon 157,
248 and 273. The hereditary mutations in p53
are associated with the Li-Fraumeni syndrome.
This syndrome indicates a higher risk of
developing different forms of cancer, including
lung cancer. Genetic testing aimed at identifying
the carriers of p53 mutations should be limited
only to high-risk groups defined on the basis of
a diagnostic pattern proposed by Lynch. In the
families with one member affected by lung
cancer the risk of developing lung cancer by
first-degree relatives is- four times higher
compared to general population risk.
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Purpose
Evaluation of preliminary (2-year)
treatment results of 7 days a week continuous
accelerated irradiation (CAIR) in compare to
convectional and concomitant radiotherapy.
Methods
One hundred and twenty eight patients
with squamous cell carcinoma of oral cavity, oro-
and hypopharynx and supraglottic larynx in stage
T2-4 NO-1 MO were randomized between 3
groups: A (study-CAIR) - 51 pts, B (control-2) - 28
pts and treated by radiation therapy alone in
1994-96. In majority (81 %) there were the
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patients in advanced clinical stage (T3+T4).
Patient and tumour characteristic, radiation
technique and volumes, total and fraction doses
were exactly the same in 3 groups of patients.
Only the overall treatment time was shorter by
about 2 weeks in CAIR group comparing to
control-1 because of the lack of weekend breaks.
The overall treatment time in CAIR and control-2
group was exactly the same because in control-2
group the "CAIR weekend fractions" were given
through the Tuesday and Fridays as a
concomitant boost.
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